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2018? Global experts look ahead in their field
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Stockholm University, Stockholm, Sweden, 5 Center for Global Health, Massachusetts General Hospital,
Boston, Massachusetts, United States of America, 6 Department of Global Health and Social Medicine,
Harvard Medical School, Boston, Massachusetts, United States of America, 7 Department of Cardiology,
Royal Perth Hospital, Perth, Australia, 8 University of Western Australia, Crawley, Australia, 9 Epicentre,
Paris, France, 10 Centre for Global Child Health, The Hospital for Sick Children, Toronto, Canada, 11 Centre
of Excellence in Women and Child Health, Aga Khan University, Karachi, Pakistan, 12 Department of Public
Health and Clinical Medicine, UmeåUniversity, Umeå, Sweden, 13 University of Aberdeen, Aberdeen,
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PLOS Medicine’s commitment to bringing research and commentary on urgent, grievous, and
underaddressed health needs to an open-access platform has never felt more relevant than in
2017. A study [1] quantifying police activity-related deaths in the United States, published in Octo-
ber, received more than 100,000 views within a few weeks of publication, and our Special Issue on
Advances in HIV Research led November to a journal record for number of articles published in a
single month. Meanwhile, requirements for sharing data, which PLOS launched in 2014, expanded
across medical publishers [2], indicating that globally important findings in health research, and
the ability to further analyze these, will become increasingly accessible in coming years.
In 2018, we plan a Special Issue on cardiovascular disease in the context of comorbid condi-
tions and another probing the interaction between climate change and health. What further
priorities must research and policy address? For our first editorial of 2018, we asked editorial
board members and other leading researchers to share their hopes, pleas, concerns, and expec-
tations for medical research and policy related to global health in 2018.
Tuberculosis research in 2018: Expect translation
Soumya Swaminathan
The past year saw unprecedented political engagement on tuberculosis (TB). The Moscow
Declaration to End TB is a promise to increase multisectoral action as well as track progress
and build accountability. The first United Nations General Assembly High-Level Meeting on
TB in 2018 will seek further commitments from heads of state, which some, like the Prime
Minister of India, have already made.
However, TB still kills more people than any other infectious disease globally, and treat-
ment of multidrug-resistant TB is a challenge. Seven countries account for 64% of the total
incidence of TB, with India leading the count, followed by Indonesia, China, Philippines, Paki-
stan, Nigeria, and South Africa [3]. Major drivers of TB include poverty, overcrowding and
undernutrition, and HIV in sub-Saharan Africa. Major gaps remain in the understanding of
pathogenesis of some forms of TB, interaction between mycobacterial lineage and host
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The coming year will likely see advances in a few areas. The establishment of international
networks of cohorts of TB patients, their household contacts, and healthy controls (e.g., Regional
Prospective Observational Research for Tuberculosis [RePORT] International) will provide the
kind of specimen repositories that basic scientists and technology developers have dreamt about,
leading to more productive translational research [5]. Better diagnostics, mainly from India and
China, are on the horizon, making it possible that every patient with suspected TB could have a
molecular diagnostic test with susceptibility testing to at least rifampicin, even at a remote primary
health center, with no electricity or highly qualified staff. More data are likely to come on the com-
bination of bedaquiline and delaminid in treating extensively drug-resistant TB.
Most exciting is the recognition that there are similarities in changes in the regulation of
immune responses to malignancies and infectious pathogens that involve modulation of com-
mon signaling pathways [6]. Identifying these specific immune cell core regulatory pathway dis-
ruptions will be key to developing new host-directed therapies for treatment and prevention.
For alcohol policy in 2018, the options are good, but expectations
are limited
Robin Room
On May 1, 2018, minimum unit pricing for alcohol comes to Scotland after a 6-year blockage
by a tooth-and-nail legal counteroffensive by alcohol industry interests. In the 6 years before it
expires if not renewed [7], the legislation is likely to have a moderate effect: one estimate is that
the new minimum price, 50p per alcohol unit, will reduce annual alcohol-attributable deaths
by 3.5% after 1 year and by double that if continued for 20 years [8].
What else can be expected in 2018 in terms of alcohol policies that would reduce alcohol-
related harm? There is broad evidence concerning policies that are effective in reducing levels
of consumption and of harm from drinking [9], but the likelihood of substantial policy
changes affecting availability or promotion is small.
Part of the problem in adopting a coherent set of alcohol policies is the wide range of types
of harm involved, for which diverse government departments are responsible. But perhaps the
biggest stumbling block is the political power of alcohol industry interests in fighting them off.
For example, in 2018, it will be interesting to watch what happens in Australia with a new
National Alcohol Strategy for 2018 to 2026. A draft has now been circulated for comments,
due by February 11, 2018. But the final strategy will need to look quite different if it is to be a
real strategy with proposed actions related to goals and clear indications of how they will be
decided and acted upon. Even at this stage, industry interests have moved to forestall an effec-
tive strategy through the media, highlighting the draft’s mention of minimum unit pricing as
one among many possible options [10]. Asked about this, the federal health minister promptly
disavowed the document [11]. Scotland’s principled and sustained action on alcohol policy
sets a standard to aim for, but in Australia, as in many other places, it will be difficult to match.
Infectious disease outbreaks in Yemen: A man-made disaster that
has a solution
Louise Ivers
One thousand days of war in Yemen have resulted in many thousands of civilian deaths as well
as deliberate destruction of health infrastructure and water infrastructure and disruption in
the payment of thousands of public servants [12]. Restrictions on imports have prevented
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access to food, medicine, and humanitarian supplies [13]. In 2017, almost 1 million cases of
suspected cholera were reported in the country, and although laboratory infrastructure is lack-
ing to confirm every single case, the sheer scale of the epidemic of watery diarrhea is stagger-
ing. Frontline workers have privately reported their fears that cholera is being deliberately
used as a weapon of war by parties to the conflict. Publicly, despite pleas from health workers
and UN agencies for humanitarian space to provide relief, blockades and bombings continue.
Diphtheria cases are now also on the rise—a painful disease, with a high mortality rate that
occurs when vaccination rates are too low.
These epidemics, as well as the dire lack of access to food (already 400,000 children with
severe acute malnourishment), do not bode well for 2018 [14]. Even if the fighting stopped
tomorrow, the impact of these health crises would be felt for a generation. The continued hos-
tilities are like a genocidal experiment to demonstrate just how badly the destruction of a
health system can destroy the health of a nation. Every one of these medical emergencies—
cholera, diphtheria, famine—is completely preventable and treatable. Without an end to the
conflict, or at a minimum an agreement to open corridors of reliable safe humanitarian access,
the ordinary people of Yemen will continue to suffer despite the fact that the public health
community has the knowledge and the tools to stop the epidemics and save lives.
Changing paradigms for atherosclerosis
Graham Hillis
In the past year, landmark studies have signaled important potential advances in our ability to
treat and prevent atherosclerotic disease.
The Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with
Elevated Risk (FOURIER) trial confirmed that evolocumab, a humanized monoclonal antibody
inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), resulted in a marked reduc-
tion in low-density lipoprotein cholesterol (LDL-C). [15] Importantly, it also demonstrated a
modest but significant reduction in adverse cardiovascular outcomes even in well-treated
patients followed up over a relatively short period [15]. Trials using bococizumab [16] and aliro-
cumab [17] suggest comparable benefits from inhibition of PCSK9, and the results of the large
Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment
With Alirocumab (ODYSSEY Outcomes) trial testing this latter agent are anticipated in 2018
[18,19]. Further studies are also underway testing alternate methods influencing lipid pathways
using small interfering RNAs and antisense oligonucleotides. LDL-C reduction with statins
greatly improves the prognosis of patients with atherosclerotic disease, and this early evidence
suggests that additional reductions using novel therapies will further reduce clinical events, but,
inevitably, the incremental benefits from further lipid lowering may diminish. Potentially the
most import recent development in the management of atherosclerotic disease has therefore
been the publication of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study
(CANTOS) [20]. This demonstrated that treatment of patients with prior myocardial infarction
and persistently elevated C-reactive protein with canakinumab, a monoclonal antibody that tar-
gets the proinflammatory cytokine interleukin 1 beta (IL-1β), reduces major cardiovascular
events [20]. Again, the reduction was modest and driven by nonfatal events. It was, however,
observed in patients who were otherwise well treated and was independent of lipid lowering.
Thus, the CANTOS trial supports the hypothesis that atherosclerosis is an inflammatory disease
and raises the prospect of treatments that target this (as yet largely unaddressed) pathogenic
mechanism. Other such therapies are currently being tested and developed.
These novel treatments are promising but extremely expensive. The challenges will be to
reduce these costs, identify those patients who may derive the most benefit, and develop safe
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and inexpensive alternatives. Only then are such therapies likely to result in a meaningful
reduction in the global burden of atherosclerotic disease.
Beyond words: US federal funding for public health and science
Rebecca Grais
According to media reports, Centers for Disease Control and Prevention (CDC) officials pro-
hibited the use of 7 words and phrases in developing budget requests [21]. CDC and US Depart-
ment of Health and Human Services (HHS) officials responded to reports by stating that there
was no ban or censorship [22,23]. Media coverage has centered on either condoning the “ban”
as evidence of the administration’s commitment to reducing government spending or on
denouncing it as yet another piece of evidence of the administration’s antiscience agenda.
There is no doubt that evidence-based policy solutions and protecting vulnerable populations
have not been a priority of this administration, with or without a word ban. Budget cuts or simply
maintaining current funding to the CDC, as well as to National Institutes of Health (NIH) and
other science and public health agencies and initiatives, will be felt directly through the scale back
of existing public health programs, research funding, and initiatives. They will be felt indirectly by
reinforcing the message that certain populations and conditions are not of interest to the US gov-
ernment. Cuts or removal of some programs, such as the HHS Secretary’s Minority AIDS Initia-
tive Fund (SMAIF) [24], which provides funding to reduce HIV-related health disparities in racial
and ethnic minority communities, would have dire consequences for the most vulnerable. Irre-
spective of whether words are banned or simply avoided by CDC staff, the consequences of such
cutbacks remain the same for vulnerable populations, whose words are often not heard at all.
Next steps for a post-transition WHO
Peter Byass
Since Dr. Tedros took over as WHO Director-General in mid-2017 [25], much has been dis-
cussed and written about WHO’s future [26,27]. Early 2018 marks the end of the beginning, as
Dr. Tedros’ new leadership team finds its feet [28]. WHO has been widely criticized for the
vertical silos in which many important issues reside. So now, with a number of discrete new
priorities having been identified [29], the overarching issue is how WHO can move forward in
an integrated way, forging essential links between important topics.
WHO’s central aim of promoting universal health coverage (UHC) is inextricably linked
with caring for increasing numbers of people living with noncommunicable diseases (NCDs)
as life expectancy increases and populations age, and UHC and NCD outcomes are critical
components of the UN Sustainable Development Goals (SDGs). Effective UHC is similarly a
prerequisite for improving reproductive and child health, targeted by other SDGs. Environ-
mental, climate-change, and emergency challenges to health are further priorities closely
linked with UHC, NCDs, and SDGs. Finally, progress across all these priorities must be mea-
surable via much-improved data at the grassroots level, forming integrated metrics.
Thus, I hope that during 2018 WHO will move on from a shopping list of priorities to a
web of interconnected tasks that can be collectively pursued at WHO’s Geneva headquarters,
in Regional Offices and within all Member States.
Global maternal and child health: Many gains, but much more remains
Zulfiqar Bhutta
The Millennium Development Goals (MDGs) concluded at the end of 2015 and were replaced
by the much anticipated SDGs [30]. While maternal and child health (MCH) enjoyed
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002498 January 30, 2018 4 / 6
tremendous primacy during the MDG period, MCH advocates and other health experts have
reason for concern: the 17 SDGs now include just 1 health-related goal (SDG3). However, the
SDGs are intimately interconnected, and a range of other goals pertain to MCH, such as SDG2
for eliminating hunger, SDG5 for achieving gender equality, SDG6 for assuring clean water
and sanitation, and many others related to sustainable and safe living environments, as well as
those addressing climate change. SDG10 for reducing inequalities is especially pertinent. Nota-
bly, while many countries achieved major reductions in maternal and child mortality during
the MDG period, others were left behind. In many instances, national averages masked tre-
mendous disparities and differentials between geographic regions and among marginalized
populations [31]. Additionally, relatively few interventions focused on going beyond survival
to addressing human development [32].
Moving forward, initiatives to address maternal and child survival, health, and development
outcomes within the SDG framework must consider opportunities for reaching hitherto mar-
ginalized populations and overcoming barriers that have constrained uniform progress. In
many countries with a high burden of maternal and child mortality, these include conflict and
humanitarian emergencies, accentuated by climate change [33]. In other instances, rapid
urbanization and rising slum populations pose challenges but also provide opportunities for
innovation and outreach [34]. Addressing these issues at an early stage of the SDGs would
ensure that the vision of UHC can be realized for all in need, everywhere!
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